HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
FRIDAY, March 16, 2007 (HealthDay News) -- Researchers will study a new test that analyzes a breast tumor's DNA in order to determine its aggressiveness and to identify which patients need chemotherapy.
The trial will involve more than 10,000 breast cancer patients across the United States.
The majority of postmenopausal women with small breast tumors don't need chemotherapy in order to reduce their risk of cancer recurrence after they've had a lumpectomy, experts explained.
"The dilemma physicians have with these patients is, because they have such small tumors, it's hard to tell who needs chemotherapy," one of the study investigators, Dr. Thomas A. Samuel, a Medical College of Georgia hematologist/oncologist who specializes in breast cancer, said in a prepared statement.
Of every 100 postmenopausal women who have a small tumor that has estrogen receptors and who have no sign of cancer spread to the lymph nodes, only about 12 to 15 require chemotherapy to reduce the risk of cancer recurrence, Samuel said.
But right now, all 100 women would likely receive chemotherapy because of a lack of tests to definitively identify who needs it and who doesn't, he said.
This study will investigate the Oncotype DX test (DXT), which looks at the DNA of the breast cancer to determine whether it's likely to spread and grow. The test looks at 16 tumor genes and uses five reference genes as controls.
The test, which costs several thousand dollars, has been on the market for more than a year but is not widely used. Participants in this U.S. government-funded Trial Assigning Individualized Options for Treatment (TAILORx) study will be assessed using the DXT.
Those with the lowest recurrence risk scores will receive radiation and hormonal treatment following lumpectomy, while those with the highest scores will also undergo chemotherapy. The patients will be followed for a minimum of five years after treatment.
Breastcancer.org has more about recurrent and metastatic breast cancer.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on June 12, 2022